MiMedx Publishes Document On Its Website Exposing False And Misleading Information Distributed By Viceroy Research And Aurelius Value

Published: Oct 02, 2017

MARIETTA, Ga., Sept. 29, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has published a document on the Company's website exposing the false and misleading information distributed by Viceroy Research and Aurelius Value in their articles on MiMedx.

Viceroy Research and Aurelius Value have each published articles about MiMedx that contained non-factual and misleading information and negative innuendo regarding MiMedx and individuals associated with the Company. In order to expose the misinformation in these attacks, MiMedx has published this document to appropriately highlight the countless falsehoods contained in these reports.  A link to the document can be found on the Company's website homepage, www.mimedx.com.

Parker H. "Pete" Petit, CEO, stated, "I encourage all MiMedx shareholders to thoroughly review and consider our document posted today on our website. As you are aware, MiMedx and all other public companies are governed by federal regulations prohibiting the dissemination of false and misleading information about the Company; unfortunately, organizations like Viceroy Research and Aurelius Value are not held to those standards and often such organizations have little to no accountability for the misinformation they publish. Both the Viceroy Research report and the Aurelius Value report indicate that either they are short in MDXG, or that the reader should assume they are short in MDXG. "

About MiMedx 
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts.   MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary Statement 
This press release includes forward-looking statements.  These statements also may be identified by words such as "believe," "except," "may," "plan," "potential," "will" and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements.  Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that different or additional facts may be discovered that change conclusions.  For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission.  Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.


View original content:http://www.prnewswire.com/news-releases/mimedx-publishes-document-on-its-website-exposing-false-and-misleading-information-distributed-by-viceroy-research-and-aurelius-value-300528467.html

SOURCE MiMedx Group, Inc.

Back to news